Three acronyms shape the life of almost every therapeutic company: IND, NDA, and BLA. They mark the major regulatory milestones in the United States, and confusing them is a common source of error among founders and investors. This essay explains what each one is, how they differ, and why the distinction matters for strategy and value. It is educational and is not investment advice.
IND: permission to begin testing in people
An Investigational New Drug application, or IND, is the request a sponsor submits before testing an experimental therapy in humans for the first time. It is not an approval to sell anything. It is permission to begin clinical research. An IND packages the preclinical safety data, the manufacturing information, and the proposed clinical protocol, and it asks the regulator to allow human testing to proceed (U.S. FDA). Clearing the IND stage is the gateway to the clinic, and everything in the clinical phases described in the founder's guide to the FDA approval process happens under an active IND.
NDA: approval to market a small-molecule drug
A New Drug Application, or NDA, is the application a sponsor submits to market a conventional, small-molecule drug after clinical testing is complete. Unlike the IND, the NDA is a request for approval to sell. It assembles the full body of evidence, the results of all clinical trials, the safety data, the proposed labeling, and the manufacturing details, and asks the regulator to conclude that the drug is safe and effective for its intended use (U.S. FDA). An approved NDA is what allows a small-molecule drug to be sold to patients.
BLA: approval to market a biologic
A Biologics License Application, or BLA, is the counterpart to the NDA for biological products, the larger, more complex therapies made from living systems, such as antibodies, vaccines, and cell and gene therapies. A BLA seeks a license to market a biologic and is reviewed under the biologics framework rather than the drug framework (U.S. FDA). The distinction is not bureaucratic. Biologics are defined as much by how they are made as by what they are, which is why the BLA carries heavy manufacturing expectations, a point developed in the analysis of the manufacturing moat.
Why the drug versus biologic distinction matters
The choice between the NDA and BLA routes is not made by the company, it follows from what the product is, but it has large strategic consequences. Biologics face manufacturing scrutiny that small molecules do not, because for a biologic the process is part of the product. They also follow different rules for competition after approval. For founders and investors, knowing which route a therapy will travel is essential to understanding its cost, its timeline, and its defensibility. The science behind many biologic therapies, at an educational level, is surveyed in the cancer research library.
How the three fit together
The sequence is straightforward once the roles are clear. A company files an IND to begin human testing, runs its clinical trials under that IND, and then, if the data support it, files either an NDA for a small molecule or a BLA for a biologic to seek approval to market. The IND is the door into the clinic. The NDA or BLA is the door into the market. Each is a distinct decision by the regulator, made on a distinct body of evidence, and each is a major value-creating or value-destroying event for the company.
Why investors should care about which is which
For investors, the distinction is not trivia. A company at the IND stage is years and several risk-laden phases away from any market, while a company with an accepted NDA or BLA under review is at the threshold of revenue. Mixing these up leads to serious mispricing of both risk and timeline. Because regulatory milestones drive most of biotech's value, as argued in why FDA strategy determines valuation, knowing exactly where a company sits in this sequence is fundamental to evaluating it, a theme connected to what makes a company investable.
The practical takeaway
IND, NDA, and BLA are not interchangeable. The IND grants permission to test in humans, the NDA grants permission to market a small-molecule drug, and the BLA grants permission to market a biologic. Understanding which applies, and where a company stands in the sequence, is basic literacy for anyone building or backing a therapeutic company. For how this regulatory map informs real-world strategy across decades of building healthcare companies, see the professional biography and the advisory practice.
Common mistakes founders make with these milestones
A few recurring errors cluster around these three applications. The first is treating the IND as a finish line rather than a starting gate, celebrating permission to begin human testing as though approval were near, when in fact the longest and riskiest part of the journey lies ahead. The second is underestimating the manufacturing demands of the BLA route, assuming that a biologic can be developed with the same process discipline as a small molecule and discovering late that the process itself must be locked down and validated. The third is misjudging timelines in investor communications, conflating the stage of an application with proximity to revenue and setting expectations that later prove impossible to meet. Each of these mistakes is avoidable with a clear understanding of what each milestone actually represents. Founders who map their regulatory sequence honestly, and who resource manufacturing and regulatory strategy early, tend to raise more credibly and stumble less, a pattern consistent with the failures described in why biotech startups fail.
Frequently asked questions
What is the difference between an IND, an NDA, and a BLA?
An IND is permission to begin testing an experimental therapy in humans. An NDA is an application to market a conventional small-molecule drug after testing. A BLA is the equivalent application to market a biologic, such as an antibody, vaccine, or cell or gene therapy.
Is an IND an approval to sell a drug?
No. An IND only grants permission to begin clinical research in humans. Approval to market comes later, through an NDA for a small-molecule drug or a BLA for a biologic, after clinical trials are complete and the evidence is reviewed.
Why does it matter whether a product follows the NDA or BLA route?
Because biologics face manufacturing scrutiny that small molecules do not, follow different post-approval competition rules, and carry different costs and timelines. The route follows from what the product is, but it shapes strategy, defensibility, and value.